Get the Stockscreener App
0.3928
9.61%
-0.0418
After Hours:
.39
-0.0028
-0.71%
Cdt Equity Inc stock is traded at $0.3928, with a volume of 79,784.
It is down -9.61% in the last 24 hours and down -40.24% over the past month.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
See More
Previous Close:
$0.4346
Open:
$0.434
24h Volume:
79,784
Relative Volume:
0.13
Market Cap:
$1.74M
Revenue:
-
Net Income/Loss:
$-20.70M
P/E Ratio:
-0.00147
EPS:
-266.6267
Net Cash Flow:
$-15.13M
1W Performance:
-18.51%
1M Performance:
-40.24%
6M Performance:
-92.91%
1Y Performance:
-99.61%
1-Day Range:
$0.3927
$0.434
1-Week Range:
$0.37
$0.5197
52-Week Range:
$0.37
$168.00
Cdt Equity Inc Stock (CDT) Company Profile
Name
Cdt Equity Inc
Sector
Industry
Phone
(646) 491 9132
Address
4851 TAMIAMI TRAIL NORTH, NAPLES
Compare CDT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDT
Cdt Equity Inc
|
0.3928 | 1.92M | 0 | -20.70M | -15.13M | -266.63 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cdt Equity Inc Stock (CDT) Latest News
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings - Bitget
CDT Equity files patents for tapinarof combination therapy - Investing.com
CDT Equity files patents for tapinarof combination therapy By Investing.com - Investing.com India
Psoriasis drug tapinarof gets 2 new patent filings as CDT targets licensing - Stock Titan
CDT Equity approves 1-for-25 reverse stock split effective Thursday - Investing.com India
Conduit to change name to CDT Equity - MSN
Cdt Equity Inc. announces reverse stock split - marketscreener.com
CDT Equity announces reverse stock split - MSN
CDT Equity Announces 1-for-25 Reverse Stock Split - TipRanks
Reverse split shrinks CDT Equity (NASDAQ: CDT) share count 25-to-1 - Stock Titan
CDT Equity Inc. Announces Reverse Stock Split - Bitget
CDT shrinks share count to about 4.7M in 1-for-25 reverse split - Stock Titan
Cdt identifies rare disease opportunities through Sarborg Signature Analysis, advancing out-licensing strategy - marketscreener.com
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy - The Manila Times
AI scan links CDT assets to rare diseases with few treatment options - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
If You Invested $1,000 in CDT Equity (CDT) - Stock Titan
CDT Equity Inc. 8-K Filing March 17, 2026: Company Details, Address, Trading Symbol, and Emerging Growth Status - Minichart
CDT Equity Shareholders Approve Major Capital Restructuring Measures - TipRanks
CDT Equity (NASDAQ: CDT) wins backing for large share issues and Cayman move - Stock Titan
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth - Bitget
Cdt Equity stockholders approve all proposals at special meeting, positioning the company for next phase of growth - marketscreener.com
Cdt Equity Stockholders Approve All Proposals At Special Meeting, Positioning The Company For Next Phase Of Growth - TradingView
CDT Equity to map asset portfolio against rare disease database By Investing.com - Investing.com India
CDT Equity to map asset portfolio against rare disease database - Investing.com South Africa
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence - The Manila Times
CDT Stock Price, Quote & Chart | CDT EQUITY INC (NASDAQ:CDT) - ChartMill
CDT Equity Expands Financing Through New Convertible Note - The Globe and Mail
Cdt Equity lowers floor price to $0.60 in purchase agreement amendment on March 3, 2026SEC filing - marketscreener.com
CDT Equity Lowers Floor Price To $0.60 In Purchase Agreement Amendment On March 3, 2026SEC Filing - TradingView
CDT Equity (CDT) lowers ELOC floor and issues $555,556 secured convertible note - Stock Titan
CDT Equity notes Sarborg patent filing for AI technology By Investing.com - Investing.com Canada
CDT Equity notes Sarborg patent filing for AI technology - Investing.com
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent - Bitget
CDT Positions for Transformational Growth - Bitget
AI and drug assets: CDT puts $115M into Sarborg to fuel growth - Stock Titan
CDT Equity Inc. announced that it has received $0.555556 million in funding - marketscreener.com
CDT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Short Interest in CDT Equity Inc. (NASDAQ:CDT) Declines By 73.3% - Defense World
CDTTW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Conduit Pharmaceuticals Expands Stake Using Equity-Funded Acquisition Strategy - The Globe and Mail
CDT Equity to Acquire 20% of Sarborg in Stock, Pre-Funded Warrants and $8 Million Cash - TradingView
CDT Equity (NASDAQ: CDT) uses shares and warrants to acquire 20% of Sarborg - Stock Titan
CDT Equity Inc. Acknowledges Sarborg Limited's Expansion of AI Signature Agent Platform into Bacteria and Agrochemicals - Quiver Quantitative
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals - Bitget
CDT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cdt Equity Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):